Key facts
- This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 21 Mar 2025, 18:09.
Neil Kumar - 19 Mar 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- BBIO
- Reported as of
- 19 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2025, 18:09:59 UTC
- Prior SEC filing
- 27 Feb 2025
- Next SEC filing
- 27 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Neil Kumar
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 21 Mar 2025.
Change
- Previous filing in this sequence was filed on 27 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBIO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +71,208
- Change %
- Price
- $0.000000
- Shares after
- 71,208
- Date
- 19 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 71,208
- Exercise price
- $33.75
- Footnotes
- F1
BBIO
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +184,860
- Change %
- Price
- $0.000000
- Shares after
- 184,860
- Date
- 19 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 184,860
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
1/16th of the shares subject to this option vest and become exercisable on May 16, 2025, and thereafter, 1/16th of the shares subject to this option will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
Footnote F2
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F3
The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2025, and thereafter, 1/16th of the underlying shares will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.